1407 Results
Sort By:
Published on February 28, 2024
A stunning response to CAR T therapy by patients with autoimmune disease was seen in a small study led by a group of German researchers. The use of CAR T in autoimmune diseases has been slowly ramping up over the last few years and this is one of the most…
Published on February 27, 2024
Researchers at the University of Pennsylvania report a variant of the p53 protein may improve the effectiveness of chimeric antigen receptor (CAR) T cell therapy. The findings are published in The Proceedings of the National Academy of Sciences and led by Carl June, MD, the Richard W. Vague Professor in…
Published on February 26, 2024
New research involving mice and with observations corroborated by fetal, neonatal, and adult human data from Cornell University demonstrates that a newborns’ T cells surpass those of adults at fighting off numerous infections. The new study clarifies why adults and infants respond differently to infection and may pave the way…
Published on February 7, 2024
A new study uncovers why natural killer (NK) cells stop actively attacking tumor cells once they infiltrate cancers and possibly offers a way to boost their activity. The researchers, from the University of Birmingham and the University of Cambridge, found evidence of why NK cells adopt a dormant state when…
Published on February 7, 2024
Researchers from Northwestern University and the University of California, San Francisco (UCSF), reporting Wednesday in the journal Nature, say they have developed a new technique to encode human T cells with a mutation found in malignant T cells that cause lymphoma. The investigators say this new immunotherapy approach is 100…
Published on January 25, 2024
Women who are diagnosed with ductal carcinoma in situ (DCIS) are around four times as likely to develop invasive breast cancer and to die from breast cancer than women in the general population, according to a study published by The BMJ this week. This increased risk lasted for at least…
Published on January 19, 2024
In a crucial Phase I/II trial, researchers at The University of Texas MD Anderson Cancer Center have reported significant success in treating patients with relapsed or refractory B-cell malignancies using cord blood-derived chimeric antigen receptor (CAR) natural killer (NK) cell therapy targeting CD19. The findings, published in Nature Medicine, show…
Published on January 3, 2024
In what could be a big step forward for immunotherapy, ”unprecedented NK [natural killer] cell-engaging Nanodrones” that can selectively target specific cancer cells have been developed, by researchers at Ulsan National Institute of Science and Technology (UNIST). This approach, the researchers suggest, could be used to address types of cancers…
Published on December 27, 2023
AstraZeneca is acquiring cell therapy developer Gracell Biotechnologies Inc. for $1.2B. Gracell is focused on cancer and autoimmune diseases and, importantly, has a toehold in China. The biotech has ten programs in preclinical or later phases. Its most advanced candidate, GC012F, is in Phase I/II trials in the U.S. and…
Published on December 20, 2023
Life is like the changing of seasons, each uniquely beautiful. Just as autumn leaves fall to the ground and make way for winter’s gentle snow, life has transformational cycles. The cycle of life continues through the changing seasons, like how the autumn winds strip the trees of their leaves and…
Published on December 11, 2023
A chimeric antigen receptor (CAR) T-cell therapy with a new cellular binding mechanism targeting CD19 has achieved good results in a Phase I trial in patients with relapsed or refractory B cell non-Hodgkin’s lymphoma. As reported in the journal Molecular Cancer, the new therapy had an overall response rate of…
Published on December 5, 2023
Research hospital Seattle Children’s announced today the spinout of its for-profit company BrainChild Bio, Inc., which will develop CAR T-cell therapies targeting pediatric central nervous system (CNS) cancers. Underpinning the new company will be a license to the CAR T-cell technology that has been developed at Seattle Children’s and will…
Published on November 22, 2023
Scientists at Stanford University have uncovered a novel physical mechanism that breast cancer cells use to break out and become invasive. They observed that in addition to established chemical methods of degrading the basement membrane, cancer cells work as a group to physically deform and tear through the basement membrane…
Published on November 20, 2023
Researchers at the University of Wisconsin-Madison report that they have identified a protein that allows for the production of norepinephrine neurons from stem cells, a development that has significant implications for research in Alzheimer’s disease (AD), Parkinson’s disease and other psychiatric and other neurodegenerative diseases. Stem-cell-derived norepinephrine neurons are found…
Published on November 9, 2023
A single, master genetic regulator can improve the effectiveness of T cells in cancer therapy and could extend their use for other diseases, researchers have discovered. A member of the BAF chromatin remodeling complex was able to reprogram T-cell genes to improve their cancer-killing abilities and reduce the chances of…